New MRI study maps rare brain disease in children
NCT ID NCT01325025
First seen Nov 20, 2025 · Last updated Jun 08, 2026 · Updated 35 times
Summary
This study used powerful MRI scans to track how a rare genetic disease called metachromatic leukodystrophy (MLD) damages the brain's white matter in young children. Researchers studied 29 children aged 1 to 6 years with MLD, along with a control group, to better understand how the disease progresses. The goal was to find new ways to measure the disease that could help select patients for future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATE INFANTILE METACHROMATIC LEUKODYSTROPHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Bâtiment Lavoisier - Unité INSERM U 663,Hôpital Necker Enfants Malades
Paris, France
-
Service de Neurologie Pédiatrique, Hôpital Bicêtre
Paris, 94275, France
-
Unité de recherche biomédicale, Neurospin, I2BM / DSV / SAC/ CEA,
Gif-sur-Yvette, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.